|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Management of hepatocellular carcinoma with portal vein tumor thrombosis: Review and update at 2016显示文摘Portal vein tumor thrombosis(PVTT) is a common phenomenon in hepatocellular carcinoma(HCC). Compared to HCC without PVTT, HCC with PVTT is characterized by an aggressive disease course, worse hepatic function, a higher chance of complications related to portal hypertension and poorer tolerance to treatment. Conventionally, HCC with PVTT is grouped together with metastatic HCC during the planning of its management, and most patients are offered palliative treatment with sorafenib or other systemic agents. As a result, most data on the management of HCC with PVTT comes from subgroup analyses or retrospective series. In the past few years, there have been several updates on management of HCC with PVTT. First, it is evident that HCC with PVTT consists of heterogeneous subgroups with different prognoses. Different classifications have been proposed to stage the degree of portal vein invasion/thrombosis, suggesting that different treatment modalities may be individualized to patients with different risks. Second, more studies indicate that more aggressive treatment, including surgical resection or locoregional treatment, may benefit select HCC patients with PVTT. In this review, we aim to discussthe recent conceptual changes and summarize the data on the management of HCC with PVTT. | Stephen L Chan Charing CN Chong Anthony WH Chan Darren MC Poon Kenneth SH Chok | 2016 | World Journal of Gastroenterology2016，22，32： | 44 |
| 2 | Th1 cytokines promote T-cell binding to antigen-presenting cells via enhanced hyaluronan production and accumulation at the immune synapse显示文摘Hyaluronan(HA)production by dendritic cells(DCs)is known to promote antigen presentation and to augment T-cell activation and proliferation.We hypothesized that pericellular HA can function as intercellular‘glue’directly mediating T cell–DC binding.Using primary human cells,we observed HA-dependent binding between T cells and DCs,which was abrogated upon pre-treatment of the DCs with 4-methylumbelliferone(4-MU),an agent which blocks HA synthesis.Furthermore,T cells regulate HA production by DCs via T cell-derived cytokines in a T helper(Th)subset-specific manner,as demonstrated by the observation that cell-culture supernatants from Th1 but not Th2 clones promote HA production.Similar effects were seen upon the addition of exogenous Th1 cytokines,IL-2,interferon c(IFN-c)and tumor necrosis factor a(TNF-a).The critical factors which determined the extent of DC–T cell binding in this system were the nature of the pre-treatment the DCs received and their capacity to synthesize HA,as T-cell clones which were pre-treated with monensin,added to block cytokine secretion,bound equivalently irrespective of their Th subset.These data support the existence of a feedforward loop wherein T-cell cytokines influence DC production of HA,which in turn affects the extent of DC–T cell binding.We also document the presence of focal deposits of HA at the immune synapse between T-cells and APC and on dendritic processes thought to be important in antigen presentation.These data point to a pivotal role for HA in DC–T cell interactions at the IS. | Paul L Bollyky Stephen P Evanko Rebecca P Wu Susan Potter-Perigo S Alice Long Brian Kinsella Helena Reijonen Kelly Guebtner Brandon Teng Christina K Chan Kathy R Braun John A Gebe Gerald T Nepom Thomas N Wight | 2010 | Cellular & Molecular Immunology2010，7，3： | 3 |
| 3 | Development of systemic therapy for hepatocellular carcinoma at 2013:Updates and insights显示文摘A growing number of multi-targeted tyrosine kinase inhibitor(TKI)has undergone testing for hepatocellular carcinoma(HCC).Unfortunately,this enthusiasm has recently been discouraged by a number of negative phaseⅢstudies on several anti-angiogenic TKIs in HCC.Several postulations have been made to account for this phenomenon,namely the plateau effects of anti-angiogenesis approach,the heterogeneity of HCC in terms of background hepatitis/cirrhosis and tumor biology,as well as the way how clinical trials are designed.Regardless of the underlying reasons,these results suggested that alternative strategies are necessary to further develop systemic therapy for HCC.Several new strategies are currently evaluated:for examples,molecular agents with activities against targets other than vascular endothelial growth factor receptor are being evaluated in on-going clinical trials.In addition,different approaches of targeted agents in combination with various treatment modalities,such as concurrently with another molecular agent,cytotoxic chemotherapy or transarterial chemoembolization,are being developed.This review aims to give a summary on the results of recently released clinical trials on TKIs,followed by discussion on some of the potential novel agents and combinational approaches.Future directions for testing innovative systemic agents for HCC will also be discussed. | Stephen L Chan Winnie Yeo | 2014 | World Journal of Gastroenterology2014，20，12： | 2 |
| 4 | Cancer Genome Scanning in Plasma: Detection of Tumor-Associated Copy Number Aberrations, Single-Nucleotide Variants, and Tumoral Heterogeneity by Massively Parallel Sequencing显示文摘 | Chan K C Allen Jiang Peiyong Zheng Yama W L Liao Gary J W Sun Hao Wong John Siu Shing Shun N Chan Wing C Chan Stephen L Chan Anthony T C Lai Paul B S Chiu Rossa W K Lo Y M D | 2013 | Clinical Chemistry2013，，1： | 2 |
| 5 | Monoclonal antibodies directed to CD20 and HLA-DR can elicit homotypic adhesion followed by lysosome-mediated cell death in human lymphoma and leukemia cells显示文摘 | Ivanov Andrei Beers Stephen A Walshe Claire A Honeychurch Jamie Alduaij Waleed Cox Kerry L Potter Kathleen N Murray Stephen Chan Claude H T Klymenko Tetyana Erenpreisa Jekaterina Glennie Martin J Illidge Tim M Cragg Mark S | 2009 | Journal of Clinical Investigation2009，，8： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员